Do exec departures portend clinical disasters? Analyst counts the examples
For many biotech observers, small corporate news can mean big things. Cancellation of a scheduled investor presentation, halting of a stock and trial switch-ups can all pique investors’ interest. Most of all, executive departures — especially ahead of late-stage clinical data — are often construed as a sign of doom.
Basic subscription required
Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.